| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| Yang,Hong-Ren | Chairman | 61.46% | SHAREHOPE MEDICINE CO., LTD. |
| Liu,Qing-Wen | Director | 61.46% | SHAREHOPE MEDICINE CO., LTD. |
| Xie,Jian-Nan | Director | 61.46% | SHAREHOPE MEDICINE CO., LTD. |
| Yang,Kun-Zhang | Director | 61.46% | SHAREHOPE MEDICINE CO., LTD. |
| Zhang,Zhang-Rong | Director | 0.49% | YANG ZHENG INVESTMENT CO., LTD. |
| Yang,Wen-Ren | Director | 0.49% | YANG ZHENG INVESTMENT CO., LTD. |
| You,Qi-Zhang | Independent Director | 0.00% | |
| Zhang,Heng-Yu | Independent Director | 0.00% | |
| Wu,Meng-Chu | Independent Director | 0.00% |
Change Company Name to MYTREX HEALTH TECHNOLOGIES, INC.
2024/07/19
Change Company Name to MINCHENG HEALTH TECHNOLOGY CO., LTD. (FORMER NAME: MINCHENG CO., LTD.)
2022/07/11
Change Person in Charge to Yang,Hong-Ren
2021/11/24
Change Company Name to MYTREX HEALTH TECHNOLOGIES, INC.
2021/08/12
Change Person in Charge to Liu,Qing-Wen
2021/01/15
Change Person in Charge to Gu,Si-Ming
2019/02/15
Change Capital to 500,000,000
2018/09/18
Change Person in Charge to Yang,Hong-Ren
2014/02/06
Change Person in Charge to Zhang,Zhang-Rong
2013/04/09
Change Person in Charge to Liu,Qing-Wen
2012/10/15
Change Person in Charge to Yang,Wen-Ren
2012/01/09
下載完整報告查看完整數據
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Operating income | 1,758,684 | 1,292,969 | 233,079 |
| Operating cost | 1,537,133 | 1,100,624 | 225,342 |
| Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
| Operating gross profit (loss) | 221,551 | 192,345 | 7,737 |
| Unrealized profit (loss) on sales of goods | - | - | - |
| Realized profit (loss) on sales of goods | - | - | - |
| Operating gross profit (loss), net | 221,551 | 192,345 | 7,737 |
| Operating expenses | 341,304 | 307,822 | 73,128 |
| Other gain (loss), net | 42,210 | 43,649 | 0 |
| Operating profit (loss) | -77,543 | -71,828 | -65,391 |
| Non-operating income and expenses | -6,778 | 14,646 | -26,419 |
| Net profit (loss) before tax | -84,321 | -57,182 | -91,810 |
| Income tax expense (benefits) | 509 | 1,108 | 1,069 |
| Net profit (loss) of ongoing business for the current period | -84,830 | -58,290 | -92,879 |
| Profit (loss) of closed units | - | - | - |
| Profit (loss) of non-jointly controlled equity before merger | - | - | - |
| Net profit (loss) for the current period | -84,830 | -58,290 | -92,879 |
| Other comprehensive profit (loss), net | 12,049 | -1,936 | -11,827 |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
| Total comprehensive profit and loss for the current period | -72,781 | -60,226 | -104,706 |
| Net profit (loss) attributable to owners of parent company | -82,375 | -56,219 | -91,901 |
| Net profit (loss) form equity attributable to former owner of business combination under common control | 0 | -1,632 | -978 |
| Net profit (loss) attributable to non-controlling interests | -2,455 | -439 | - |
| Comprehensive profit (loss) attributable to owners of parent company | -70,430 | -58,154 | -103,916 |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | 0 | -1,632 | -790 |
| Comprehensive profit (loss) attributable to non-controlling interests | -2,351 | -440 | - |
| Basic earnings per share (yuan) | -2 | -1 | -2 |
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net cash inflow (outflow) from operating activities | 31,630 | -4,255 | 2,281 |
| Net cash inflows (outflows) from investing activities | 63,363 | -268,291 | -75,882 |
| Net cash inflow (outflow) from financing activities | -40,376 | 5,411 | 4,755 |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | 1,746 | -736 | 2,234 |
| Increase (decrease) in cash and cash equivalents in the current period | 56,363 | -267,871 | -66,612 |
| Beginning balance of cash and cash equivalents | 218,656 | 486,527 | 471,209 |
| Ending balance of cash and cash equivalents | 275,019 | 218,656 | 404,597 |
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current asset | 691,635 | 671,934 | 506,809 |
| Non-current asset | 454,043 | 586,255 | 328,717 |
| Total asset | 1,145,678 | 1,258,189 | 835,526 |
| Current liability | 405,148 | 441,752 | 69,836 |
| Non-current liability | 131,222 | 138,966 | 32,829 |
| Total liability | 536,370 | 580,718 | 102,665 |
| share capital | 365,356 | 365,356 | 365,356 |
| Equity - secruity token | - | - | - |
| capital reserve | 291,457 | 291,457 | 288,253 |
| retained earning | -52,395 | 32,974 | 89,123 |
| Other equity | -4,244 | -14,943 | -12,938 |
| Treasury stock | - | - | - |
| Total equity attributable to owners of parent company | 600,174 | 674,844 | 729,794 |
| Equity attributable to former owner of business combination under common control | 0 | 0 | - |
| Equity attributable to non-controlling interest before business merger under common control | - | - | - |
| Non-controlling interests | 9,134 | 2,627 | 3,067 |
| Total Equity | 609,308 | 677,471 | 732,861 |
| Share capital awaiting retirement (unit: share) | 0 | 0 | 0 |
| Issued shares of advance equity (unit: shares) | 0 | 0 | 0 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 0 | 0 | 0 |
| Net asset value per share | 16 | 18 | 19 |
